|
Synonyms: Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
mirvetuximab soravtansine is an approved drug (FDA (2022))
Compound class:
Antibody
Comment: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that delivers the cytotoxic maytansinoid DM4 (a microtubule toxin) to cancer cells that express the folate receptor α (FOLR1; P15328) [2]. FOLR1 is an active oncology drug target [10]. Mirvetuximab soravtansine has proven particularly effective against FLOR1 +ve, advanced ovarian tumours [1,5,9].
The chemical structure of DM4 and its sulfo-SPDB linker is represented in PubChem CID 131704480. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2022)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10176 | mirvetuximab soravtansine |
| Synonyms |
| Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 575 |
| Other databases | |
| GtoPdb PubChem SID | 473153838 |
| Search PubMed clinical trials | mirvetuximab soravtansine |
| Search PubMed titles | mirvetuximab soravtansine |
| Search PubMed titles/abstracts | mirvetuximab soravtansine |
